What happened
EyePoint, Inc. (NASDAQ: EYPT) said on October 19, 2026 that it is shifting its focus to DURAVYU for diabetic macular edema after LUCIA missed its primary endpoint.
The board approved a plan to cut the workforce by about 53% and end the pivotal Phase 3 wet AMD trials early, before the second year of each trial is fully completed.
The company said the move is meant to lower operating costs and direct more resources to the late-stage DME program.
EyePoint said the changes should produce about $30 million in estimated annualized savings.
It also expects about $9 million in aggregate charges tied to employee separation benefits, including severance and related expenses.
The Phase 3 DME program includes COMO and CAPRI, two global, randomized, double-masked, aflibercept-controlled, non-inferiority trials of DURAVYU 2.7 mg.
EyePoint said it had about $118 million in cash, cash equivalents and short-term investments as of September 30, 2026.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Estimated annualized savings | $30 million | EyePoint press release | |
| Workforce reduction | 53% | EyePoint press release | |
| Aggregate separation charges | $9 million | EyePoint press release | |
| Cash, cash equivalents and short-term investments | $118 million | EyePoint press release |
Read more: EyePoint (EYPT) stock analysis and investment case
Why it matters
OptimistFi's case is that DURAVYU still needs to show six-month sustained vorolanib delivery can match aflibercept outcomes while lowering injection burden.
This filing is mixed for that view because EyePoint is ending the wet AMD trials early after LUCIA failed the primary non-inferiority endpoint.
The DME program remains in place, so the investment case now depends more narrowly on that result.
OptimistFi's calculation puts the annualized savings at about 3.3 times the announced separation charges.
That matters because the company is cutting about half the workforce while it waits for a fourth-quarter 2027 topline readout in DME.
The $9 million charge is a one-time separation cost, while the wet AMD program is being wound down before the DME data arrive.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
EyePoint said most of the workforce cuts should happen in the fourth quarter of 2026 and be finished in the first half of 2027.
The company expects pivotal Phase 3 topline data for DURAVYU in DME in the fourth quarter of 2027.
Those dates set the next test of whether the refocus can support the company after the wet AMD trials end early.
A stronger DME readout would support the shift, while a weaker one would hurt it.
Until then, the filing mainly shows a cash-conservation plan and a narrower clinical path.
More from OptimistFi
- EYPT stock: the EyePoint thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Top perps movers today: stocks, commodities, FX and indices
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
- Perps news: leveraged stocks, gold, FX and crypto on-chain
Sources
- EyePoint press release — Exhibit 99.1 announcing the strategic prioritization, workforce reduction, savings, charges and DME timeline.
- SEC 8-K — Current report describing the board-approved prioritization plan and the timing of the workforce reduction.
Read the full OptimistFi thesis on EyePoint, Inc.: https://optimistfi.com/stocks/EYPT
See what would break the EyePoint, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full EyePoint, Inc. investment case, its status and the next test to watch live on the EyePoint, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
